*Dietary Reference Intake not established.
Other ingredients: None. Capsule: hypromellose, sorbitol, silicon dioxide, water.
AOR guarantees that no ingredients not listed on the label have been added to the product. Contains no wheat, gluten, corn, nuts, soy, eggs, fish or shellfish.
Suggested Use
Take one to two capsules per day on an empty stomach, at least two hours before or after food, calcium or milk but ensure that daily calcium intake is adequate. Calcium, food and milk products significantly reduce strontium absorption if taken at the same sitting.
Main Applications
• Supports skeletal health
Source
• Pharmaceutical synthesis (Strontium citrate)
• Bovine Milk (MBP)
Pregnancy / Nursing
No studies, best to avoid.
Cautions
Not recommended for children, adolescents, pregnant/nursing women or people with milk allergies. Do not take if you are taking tetracycline or quinolone antibiotics. Talk to your health care practitioner before taking if you have kidney disease.
|
Bone health is one of the greatest concerns in our society. 1 in 3 women over the age of 50 will suffer osteoporotic fractures, as will 1 in 5 men. With such statistics, advances in bone health are a main focus of current research. Some treatments for osteoporosis are inconvenient and associated with side effects. Other solutions may work by similar mechanisms, and some are incompatible with each other. Milk Basic Protein (MBP, found in Advanced Bone Protection) and Strontium are two novel and effective nutrients that work through different mechanisms for a synergistic effect.
|
Advanced Bone Protection
Advanced Bone Protection contains Milk Basic Protein (MBP), a nutrient extracted from the whey fraction of milk. The terms ‘milk’ and ‘protein’ refer to the source and type of nutrient respectively, while the term ‘basic’ refers to its alkaline nature.
MBP greatly improves the absorption and retention of calcium within the bones, and it does so in a unique way. Part of MBP’s structure consists of a protein strain known as cystatin C, which inhibits an enzyme called cystein protease. Cystein protease releases calcium from bone and digests collagen in the bone matrix. MBP’s cystatin C blocks this enzyme, as well as other factors that contribute to calcium release from bone.
MBP also enhances the proliferation and activity of bone-building cells called osteoblasts, while at the same time preventing the proliferation and activity of bone-breaking cells (osteoclasts). MBP is capable of suppressing the activity of even the most isolated osteoclast. MBP’s ability to manipulate osteoblasts into producing more collagen is more pronounced than that of other nutrients for bone health.
MBP also increases serum concentrations of osteocalcin, which is the major non-collagenous protein in bone.
Studies with MBP:
• In a study among healthy menopausal women, the MBP group reported a bone mineral density (BMD) increase of 1.21% while the placebo group recorded a 0.66% BMD decrease.
• In another study among healthy adult women, the MBP group gained approximately 70% more bone mineral density than the control group.
• MBP reduced the number of pits on the bone surface caused by bone resorption by approximately 85% in an in-vitro study.
• In yet another study among healthy adult females, the MBP group displayed a 3% increase in the BMD of the radius (a forearm bone near the wrist) compared to a 1.3% BMD decrease in the placebo group.
• MBP was given to a group of normal healthy adult men, after 16 days their serum osteocalcin concentration had increased significantly, urinary markers of bone resorption had decreased significantly, suggesting that MBP promoted bone formation and suppressed bone resorption while maintaining the balance of bone remodeling.
Strontium
Strontium is a mineral that is thought by many to be essential for the normal development, structure, function and health of the skeletal system. Unlike the existing drugs for osteoporosis treatment, as well as calcium and vitamin D, strontium does not work only by reducing bone resorption, but it actually increases the formation of new bone tissue. Furthermore, animal studies have shown that it boosts bone strength without a negative impact on bone quality, even at extremely high doses.
Strontium works by causing bone building osteoblasts to multiply more quickly, and cellular studies have shown that it causes bone tissue cultures to synthesize more bone matrix and new bone collagen.
One of the main ways strontium exerts its bone building effects is by activating the calcium-sensing receptor (CaR). CaRs are found throughout the body, including in the bones, the kidneys, the gastrointestinal system and several glands of the endocrine system, which are constituents of the body that are central to the regulation of calcium levels. These receptors are activated when calcium attaches to them. CaRs are found on the cells of the parathyroid gland, where parathyroid hormone (PTH) is secreted in response to low calcium levels and causes calcium to be released from bones. Strontium binds to CaRs to prevent the release of PTH.
CaR receptors are responsible for releasing calcitonin from the thyroid, a hormone which blocks the activity of osteoclasts and prevents urinary loss of calcium. CaRs are also found on osteoblasts, and when strontium attaches, they stimulate the proliferation of these bone building cells, making them more active and causing them to deposit more calcium, effectively building bone.
The benefits of strontium’s effects have been impressively demonstrated by clinical trials, which have shown that strontium reduces fracture rates at all sites, including hip and vertebral areas which are the most common fracture areas associated with osteoporosis. Strontium can also reduce the rate of height loss and free patients of back pain.
In Partnership
The mechanisms of Advanced Bone Protection and Strontium are distinct, yet synergistic. Strontium increases bone formation, while MBP reduces the rate at which bone is destroyed. Their actions reduce bone breakdown without reducing the activity of bone building cells. The combination of these two nutrients is therefore a perfect match for effective bone support.
References
Aoe S, et al. A controlled trial of the effect of milk basic protein (MBP) supplementation on bone metabolism in healthy menopausal women. Osteoprosis International. 2005 Dec;16(12):2123-8. Epub 2005 Aug 31.
Aoe S, et al. Controlled Trial of the Effects of Milk Basic Protein (MBP) Supplementation on Bone Metabolism in Healthy Adult Women. Biosci. Biotechnol. Biochem. Vol.65 pp.913-918. 2001.
Matsuoka Y, et al. Cystatin C in Milk Basic Protein (MBP) and Its Inhibitory Effect on Bone Resorption in Vitro. Biosci. Biotechnol. Biochem. 2002. Vol.66 pp.2531-2536.
Takada Y, et al. Milk Basic Protein Increases Bone Mineral Density and Improves Bone Metabolism In Humans. Nutritional Aspects of Osteoporosis 2nd Ed. (2004); pp. 413-429.
Toba S, et al. Milk Basic Protein Promotes Bone Formation and Suppresses Bone Resorption in Healthy Adult Men. Biosci. Biotechnol. Biochem. Vol.65 pp.1353-1357. 2001
Sips, AJAM et-al. Intestinal absorption of strontium chloride in healthy volunteers: pharmacokinetics and reproducibility.Br. J Clin Pharmacol. 1996;41:543-549
Sips, AJAM.Absoption kinetics of strontium and calcium in human and experimental animal. Ph.D Thesis. University of Amsterdam. 1994
Skoryna, SC. Effects of oral supplementation with stable strontium. Can Med J. 1981;125:703-712
ATSDR.Toxicological profile for strontium. Atlanta,GA: Agency for toxic substances and disease registry US Dept of Health and Human Services. Public Health Services.2001
Leeuwenkamp,OR et-al. Human pharmacokinetics of orally administered strontium. Calcif. Tissue Int. 1990;47:136-140
Marie,PJ et-al. Effect of low doses of stable strontium on bone metabolism in rats. Mineral Electrolyte Metab. 1985;11:5-13
Shorr, E and Carter, AC. The value of strontium as an adjuvant to calcium in the mineralization of the skeleton in osteoporosis in man. Conference on Metabolic Interactions. Eds. EC Reifenstein Jr.,NY.NY.Pub J Macy Foundation 1950 pp144-154.
McCaslin FE and Janes, HM. The effect of strontium lactate in the treatment of osteoporosis. Proc. Mayo Clinic. 1959;34:329-334
Skoryna,SC and Fuskova, M. In: Skoryna, SC ed. Handbook of stable strontium.NY;Plenum:1985.p593-617
Comar,CL , Wasserman, RH and Nold, NM. Strontium-Calcium discrimination factors in the rat. Proc. Sco. Exp. Biol. Med.1950;92:859-863
Della Rossa et-al. Absorption and retention of ingested strontium and calcium in beagles as a function of age. Nature.1965;205:197-198
Skoryna, SC.Metabolic aspects of the pharmacologic uses of trace elements in human subjects with specific references to stable strontium. Trace Subst. Enviorn Health.1984;18:3-23
Dahl, SG et-al. Incorporation and distribution of strontium in bone. Bone.2001;28:446-453
Storey,E. Strontium “rickets” bone calcium and strontium changes. Austral.Ann. Med. 1961;10:213-222
Matsumoto, A. Effect of strontium chloride on bone resorption induced by prostaglandin E2 in cultured bone. Arch. Toxicol. 1988;62:240-241
Marie,PJ et-al. Mechanisms of action and therapeutic potential of strontium in bone. Calcif. Tissue Int.2001;69:121-129.
|
|
